Blurbs

Analysts’ Top Healthcare Picks: Larimar Therapeutics (LRMR), SCYNEXIS (SCYX)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Larimar Therapeutics (LRMRResearch Report) and SCYNEXIS (SCYXResearch Report) with bullish sentiments.

Larimar Therapeutics (LRMR)

JMP Securities analyst Jonathan Wolleben reiterated a Buy rating on Larimar Therapeutics today and set a price target of $16.00. The company’s shares closed last Thursday at $3.07, close to its 52-week low of $1.53.

According to TipRanks.com, Wolleben is ranked 0 out of 5 stars with an average return of -14.2% and a 27.2% success rate. Wolleben covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Crinetics Pharmaceuticals, and Madrigal Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Larimar Therapeutics with a $12.67 average price target.

See Insiders’ Hot Stocks on TipRanks >>

SCYNEXIS (SCYX)

Maxim Group analyst Jason McCarthy maintained a Buy rating on SCYNEXIS yesterday and set a price target of $7.00. The company’s shares closed last Thursday at $1.89, close to its 52-week low of $1.70.

According to TipRanks.com, McCarthy ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -38.9% and a 14.0% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Genenta Science SpA Sponsored ADR, Reviva Pharmaceuticals Holdings, and Brainstorm Cell Therapeutics.

Currently, the analyst consensus on SCYNEXIS is a Strong Buy with an average price target of $9.50, which is a 397.4% upside from current levels. In a report released today, Ladenburg Thalmann & Co. also maintained a Buy rating on the stock with a $15.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on LRMR:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More